AstraZeneca plc (AZN) Given Underperform Rating at Credit Suisse Group, Report finds

AstraZeneca plc (AZN) Given Underperform Rating at Credit Suisse Group, Report finds

Credit Suisse Group reiterated their underperform rating on shares of AstraZeneca plc (LON:AZN) in a research note issued to investors on Friday. They currently have a GBX 4,000 ($49.83) price objective on the biopharmaceutical company’s stock.

Several other research firms also recently weighed in on AZN. Goldman Sachs Group, Inc. (The) set a GBX 4,000 ($49.83) target price on AstraZeneca plc and gave the stock a sell rating in a research report on Wednesday, October 19th. BNP Paribas reiterated a neutral rating and set a GBX 5,100 ($63.53) target price on shares of AstraZeneca plc in a research report on Sunday, January 15th. Investec assumed coverage on AstraZeneca plc in a research report on Monday, January 23rd. They set a hold rating and a GBX 4,600 ($57.30) target price for the company. Deutsche Bank AG restated a buy rating and set a GBX 6,200 ($77.23) price target on shares of AstraZeneca plc in a research note on Friday, November 11th. Finally, Liberum Capital restated a hold rating and set a GBX 5,200 ($64.77) price target on shares of AstraZeneca plc in a research note on Thursday, December 8th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. AstraZeneca plc currently has a consensus rating of Hold and an average target price of GBX 4,878.29 ($60.77).

Shares of AstraZeneca plc (LON:AZN) opened at 4484.50 on Friday. The firm’s 50-day moving average is GBX 4,406.01 and its 200 day moving average is GBX 4,675.89. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The company’s market capitalization is GBX 56.73 billion.

The firm also recently disclosed a dividend, which will be paid on Monday, March 20th. Stockholders of record on Thursday, February 16th will be issued a GBX 150.20 ($1.87) dividend. The ex-dividend date of this dividend is Thursday, February 16th. This represents a dividend yield of 3.52%. This is an increase from AstraZeneca plc’s previous dividend of $68.70.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Related posts

Leave a Comment

AstraZeneca plc (AZN) Given Underperform Rating at Credit Suisse Group

AstraZeneca plc (AZN) Given Underperform Rating at Credit Suisse Group

Credit Suisse Group reiterated their underperform rating on shares of AstraZeneca plc (LON:AZN) in a research note issued to investors on Friday. They currently have a GBX 4,000 ($49.83) price objective on the biopharmaceutical company’s stock.

Several other research firms also recently weighed in on AZN. Goldman Sachs Group, Inc. (The) set a GBX 4,000 ($49.83) target price on AstraZeneca plc and gave the stock a sell rating in a research report on Wednesday, October 19th. BNP Paribas reiterated a neutral rating and set a GBX 5,100 ($63.53) target price on shares of AstraZeneca plc in a research report on Sunday, January 15th. Investec assumed coverage on AstraZeneca plc in a research report on Monday, January 23rd. They set a hold rating and a GBX 4,600 ($57.30) target price for the company. Deutsche Bank AG restated a buy rating and set a GBX 6,200 ($77.23) price target on shares of AstraZeneca plc in a research note on Friday, November 11th. Finally, Liberum Capital restated a hold rating and set a GBX 5,200 ($64.77) price target on shares of AstraZeneca plc in a research note on Thursday, December 8th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. AstraZeneca plc currently has a consensus rating of Hold and an average target price of GBX 4,878.29 ($60.77).

Shares of AstraZeneca plc (LON:AZN) opened at 4484.50 on Friday. The firm’s 50-day moving average is GBX 4,406.01 and its 200 day moving average is GBX 4,675.89. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The company’s market capitalization is GBX 56.73 billion.

The firm also recently disclosed a dividend, which will be paid on Monday, March 20th. Stockholders of record on Thursday, February 16th will be issued a GBX 150.20 ($1.87) dividend. The ex-dividend date of this dividend is Thursday, February 16th. This represents a dividend yield of 3.52%. This is an increase from AstraZeneca plc’s previous dividend of $68.70.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Related posts

Leave a Comment